CA2239787A1 - Potentialisation des proprietes d'inhibition du complement et de la coagulation d'un inhibiteur de c1 - Google Patents

Potentialisation des proprietes d'inhibition du complement et de la coagulation d'un inhibiteur de c1 Download PDF

Info

Publication number
CA2239787A1
CA2239787A1 CA 2239787 CA2239787A CA2239787A1 CA 2239787 A1 CA2239787 A1 CA 2239787A1 CA 2239787 CA2239787 CA 2239787 CA 2239787 A CA2239787 A CA 2239787A CA 2239787 A1 CA2239787 A1 CA 2239787A1
Authority
CA
Canada
Prior art keywords
inhibitor
esterase inhibitor
inhibition
complement
dxs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2239787
Other languages
English (en)
Inventor
Cornelis Erik Hack
Walter Wuillemin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Sanquin Bloedvoorziening
Original Assignee
Stichting Sanquin Bloedvoorziening
Cornelis Erik Hack
Walter Wuillemin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening, Cornelis Erik Hack, Walter Wuillemin filed Critical Stichting Sanquin Bloedvoorziening
Priority claimed from PCT/NL1996/000488 external-priority patent/WO1997022347A1/fr
Publication of CA2239787A1 publication Critical patent/CA2239787A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2239787 1995-12-18 1996-12-18 Potentialisation des proprietes d'inhibition du complement et de la coagulation d'un inhibiteur de c1 Abandoned CA2239787A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95203537.6 1995-12-18
EP95203537 1995-12-18
PCT/NL1996/000488 WO1997022347A1 (fr) 1995-12-18 1996-12-18 Potentialisation des proprietes d'inhibition du complement et de la coagulation d'un inhibiteur de c1

Publications (1)

Publication Number Publication Date
CA2239787A1 true CA2239787A1 (fr) 1997-06-26

Family

ID=29404049

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2239787 Abandoned CA2239787A1 (fr) 1995-12-18 1996-12-18 Potentialisation des proprietes d'inhibition du complement et de la coagulation d'un inhibiteur de c1

Country Status (1)

Country Link
CA (1) CA2239787A1 (fr)

Similar Documents

Publication Publication Date Title
Wuillemin et al. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma.
Day et al. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit
Hara et al. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats
EP0497756B1 (fr) Composition antithrombose
EP0473564B1 (fr) Combinaison anticoagulante de LACI et de polysaccharides sulfatés
Turpie Fondaparinux: a factor Xa inhibitor for antithrombotic therapy
US5777081A (en) Process for producing an inter-alpha-trypsin inhibitor concentrate for therapeutic use and concentrate thus obtained
Abildgaard Antithrombin–early prophecies and present challenges
EP0868191A1 (fr) Potentialisation des proprietes d'inhibition du complement et de la coagulation d'un inhibiteur de c1
Wuillemin et al. Inactivation of factor XIa in vivo: studies in chimpanzees and in humans
Okamura et al. Treatment of disseminated intravascular coagulation and its prodromal stage with gabaxate mesilate (FOY): a multi-center trial
EP0535129A1 (fr) Preparation anticoagulante.
Mauron et al. Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins
CA2239787A1 (fr) Potentialisation des proprietes d'inhibition du complement et de la coagulation d'un inhibiteur de c1
Kaiser et al. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans
Wuillemin et al. Clearance of human factor XIa–inhibitor complexes in rats
Andersson et al. Mechanisms of anticoagulant effects of some sulphated polysaccharides
Bridey et al. Recombinant hirudin (HBW 023): Biological data of ten patients with severe venous thrombo‐embolism
Kaiser et al. Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders
US6291427B1 (en) Anticoagulant combination of LACI and sulfated polysaccharides
Steinbuch Regulation of protease activity
Rodeghiero et al. Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia
Kaiser et al. A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans
Samama et al. Anticoagulation: the old and the new
Dickneite et al. Antithrombin III and Tissue Factor Pathway Inhibitor: Two Physiologic Protease Inhibitors of the Coagulation System

Legal Events

Date Code Title Description
FZDE Dead